Thieler Law Corp advises investors with losses exceeding $100,000 of the December 12, 2016 lead plaintiff deadline in a class action lawsuit filed against Mylan N.V. (NASDAQ: MYL) (“Mylan” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Mylan N.V. securities between February 28, 2013 and October 7, 2016, have until December 12, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Mylan N.V. securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that  Mylan N.V. and Mylan Inc wrongly classified EpiPen as a generic under the Medicaid Drug Rebate Program, which was financially consequential for federal and state governments as it reduced the amount of quarterly rebates Mylan N.V. and Mylan Inc owed for EpiPen; between 2011 through 2015, Mylan N.V. and Mylan Inc paid a lower rebate of 13% when it should have been paying a higher rebate of 23.1% or more; the incorrect classification appears to have cost the federal government more than $100 million in the last five years alone; in turn, Mylan N.V. and Mylan Inc lacked effective internal controls over financial reporting.

On October 5, 2016, a report issued by the Centers for Medicare and Medicaid Services ("CMS") claimed that Mylan had overcharged the U.S. Medicaid health program for the Company’s EpiPen shot, despite being told that Mylan needed to provide larger discounts under the law. The letter claimed that the government had "expressly told Mylan that the [EpiPen] product is incorrectly classified."

Following this news, NASDAQ: MYL dropped $1.19 per share, or 3.13%, to close at $36.84 on October 6, 2016.

If you were negatively impacted by your investment in Mylan N.V. securities between February 28, 2013 and October 7, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185